BTK
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB09980 | Zanubrutinib | 1691249-45-2 | Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor. |
| FB12110 | Vecabrutinib | 1510829-06-7 | Vecabrutinib is a potent BTK inhibitor, with IC50s of 4.6 nM and 1.1 nM for WT BTK and C481S BTK, respectively, and also inhibits ITK activity (IC50, 24 nM). |
| FB19564 | SJF620 | 2376187-16-3 | SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN. |
| FB08621 | RN486 | 1242156-23-5 | RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM. |
| FB00518 | QL47 | 1469988-75-7 | QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM. |
| FB11212 | Poseltinib | 1353552-97-2 | Poseltinib is a tyrosine kinase inhibitor of Bruton's tyrosine kinase (BTK). |
| FB11298 | PLS-123 | 1431727-04-6 | PLS-123 is a covalent irreversible Btk inhibitor with potential anti-proliferative activity. |
| FB15639 | PF-06250112 | 1609465-89-5 | PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5nM, 0.9nM and 1.2nM for BTK, BMX Kinase and TEC, respectively. |
| FB06972 | PCI-32765 Racemate | 936563-87-0 | PCI-32765 racemate is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. |
| FB02199 | Ibrutinib | 936563-96-1 | PCI-32765 is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. |
| FB04901 | PCI-29732 | 330786-25-9 | PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay. |
| FB17735 | Orelabrutinib | 1655504-04-3 | Orelabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. |
| FB03233 | ONO-4059 HCl | 1439901-97-9 | ONO-4059 is a selective inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development. |
| FB02781 | ONO-4059 | 1351636-18-4 | ONO-4059 is a highly selective BTK inhibitor with IC50 of 2.2 nM. |
| FB02780 | ONO-4059 Analog | 1351635-67-0 | ONO-4059 Analog is a highly selective BTK inhibitor with IC50 of 2.2 nM. |
| FB11880 | MT-802 | 2231744-29-7 | MT-802 (MT802) is a potent BTK PROTAC that induces degradation of both wild-type and C481S mutant BTK (DC50=9.1 nM); MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome; MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK, elicits complete BTK knockdown at 250 nM; reduces the pool of active, phosphorylated BTK in cells isolated from CLL patients with the C481S mutation, whereas ibrutinib cannot. |
| FB10935 | MDVN1003 | 2058116-54-2 | MDVN1003 is a potent inhibitor of BTK amd PI3K delta. |
| FB10936 | MDVN1003 Enantiomer | 2058116-52-0 | MDVN1003 is a potent inhibitor of BTK amd PI3K delta. |
| FB10142 | Ibrutinib-biotin | 1599432-18-4 | Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, with an IC50 of 0.755-1.02 nM for BTK. |
| FB10147 | GDC-0853 | 1434048-34-6 | GDC-0853 is a potent and orally BTK inhibitor. |
| FB00869 | GDC-0834 S-Enantiomer | 1133432-50-4 | GDC-0834 S-enantiomer is the S-enantiomer of GDC-0834. |
| FB02281 | GDC-0834 Racemate | 1133432-46-8 | GDC-0834 racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively. |
| FB02282 | GDC-0834 | 1133432-49-1 | GDC-0834 is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively. |
| FB11211 | Evobrutinib | 1415823-73-2 | Evobrutinib is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Preclinical research suggests it may be therapeutically useful in certain autoimmune diseases. |
| FB01142 | CNX-774 | 1202759-32-7 | CNX-774 is a potent and selective of Btk with IC50 < 1 nM. |
| FB09999 | CHMFL-BTK-01 | 2095280-64-9 | CHMFL-BTK-01 is an irreversible BTK inhibitor targeting Cys481 residue while completely abolishing BMX, JAK3 and EGFR's activity. |
| FB00517 | CGI-1746 | 910232-84-7 | CGI-1746 is a Bruton's tyrosine kinase (Btk) inhibitor. |
| FB11878 | BTK PROTAC 9 | N/A | BTK PROTAC 9 is a potent PROTAC for BTK with DC50 of 5.9 nM in cultured Ramos cells, requires simultaneous engagement of BTK and CRBN to effectively degrade BTK; TEC, a closely related protein to BTK that potently binds BTK PROTAC 9 is also degraded. |
| FB11877 | BTK PROTAC 10 | N/A | BTK PROTAC 10 is a potent PROTAC for BTK with DC50 of 1.1 nM in cultured Ramos cells; can successfully delivered to tissues and can specifically degrade BTK in vivo, in a dose-dependent and tissue-biased manner by s.c. administration. |
| FB16841 | BTK inhibitor 4b | 1646608-10-7 | BTK inhibitor 4b is a highly selective BTK inhibitor with significant efficacy in models in vivo and good ADME and safety profiles. |
| FB09241 | Btk Inhibitor 1 R-Enantiomer | 1022150-12-4 | Btk inhibitor 1 R-enantiomer is a Btk kinase inhibitor. |
| FB03294 | Btk Inhibitor 1 R-Enantiomer HCl | 1553977-42-6 | Btk inhibitor 1 R-enantiomer HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor. |
| FB03178 | Btk Inhibitor 1 | 1412418-47-3 | Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor. |
| FB10145 | Btk inhibitor 1 HCl | 1807619-60-8 | Btk inhibitor 1 HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor. |
| FB11213 | BMS-986142 | 1643368-58-4 | BMS-986142 is a potent, selective, reversible BTK inhibitor. BMS-986142 shows BTK IC50 = 0.5nM and human WB IC50 = 90 nM. |
| FB09956 | BMS-935177 | 1231889-53-4 | BMS-935177 is a potent BTK inhibitor with improved kinase selectivity and superior oral exposure in multiple species. should provide useful clinical efficacy in autoimmune diseases. |
| FB11074 | Zanubrutinib (Recemate) | 1633350-06-7 | BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. |
| FB00686 | AVL-292 | 1202757-89-8 | AVL-292 is a covalent and highly selective inhibitor of Btk with IC50 of 0.5 nM, exhibiting > 1400-fold selectivity over the other kinases assayed. |
| FB02797 | AVL-292 Benzenesulfonate | 1360053-81-1 | AVL-292 benzenesulfonate is a potent inhibitor of Btk kinase activity (IC50< 0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays. |
| FB11536 | ARQ 531 | 2095393-15-8 | ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity. |
| FB00823 | Acalabrutinib | 1420477-60-6 | Acalabrutinib is a second-generation, selective and irreversible inhibitor of BTK (Bruton's tyrosine kinase) with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay. Acalabrutinib has improved pharmacologic features, including favorable plasma exposure, rapid oral absorption, a short half-life, and the absence of irreversible targeting to alternative kinases. |
| FB12167 | (-)-Terreic Acid | 121-40-4 | (-)-Terreic Acid is a selective inhibitor of Bruton's tyrosine kinase (BTK). |